A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis
This study tests a weekly injection called survodutide to see if it helps adults with a specific type of fatty liver disease known as MASH. Researchers want to find out if the medicine can safely improve liver health and reduce liver scarring over time.
You may be able to join if you are 18 or older, live with obesity, and have a confirmed diagnosis of MASH with moderate to advanced liver scarring. People with certain other liver conditions, history of heavy alcohol use, or abnormal liver function blood tests cannot take part.
Participants will be randomly assigned to receive either the study medicine or a placebo, which looks like the medicine but has no active ingredients. You will inject the treatment under your skin once a week and receive guidance on diet and exercise while attending regular check-ups over several years.
The study has multiple locations in the United States, including cities in Alabama and Arizona, and is currently actively recruiting participants.
- 1Tests the medicine survodutide for MASH and liver scarring
- 2Involves weekly self-injections and lifestyle coaching for diet and exercise
- 3Study is currently recruiting participants at multiple locations
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.